Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment
NCT00013585Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in HIV-associated cognitive impairment comparing STS with Placebo -> STS (2 arms). Primary endpoints: Change in cognitive performance at 24 weeks and Frequencies of adverse experiences, abnormal results on laboratory tests, changes over time in laboratory tests and vital signs at 24 weeks. Status: completed.
02
Drugs
selegiline
03
Conditions
HIV-associated cognitive impairment
Beyond the preview
Go deeper on NCT00013585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00013585.